TNF and Behcet disease: Should this approach prove ineffective, anti-TNF agents may be considered.[61] An observational cohort study assessing the safety and efficacy of the IL-6 receptor inhibitor tocilizumab in Behçet’s disease with refractory arterial involvement indicated that tocilizumab is both safe and effective, additionally reducing the necessity for steroids and immunosuppressants.[62]